Jazz Pharmaceuticals JAZZ Non-deductible IPR&D charges
Non-deductible IPR&D charges at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's non-deductible ipr&d charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's non-deductible ipr&d charges?
- Jazz Pharmaceuticals (JAZZ) reported non-deductible ipr&d charges of $46.84M in Q4 2025.
- What does non-deductible ipr&d charges mean?
- The tax cost associated with R&D expenses that cannot be deducted from taxable income.
- How do you interpret non-deductible ipr&d charges?
- High non-deductible charges increase the effective tax rate and reduce net income.
- How does non-deductible ipr&d charges compare across companies?
- Common in biopharma companies that frequently acquire other firms and their R&D pipelines.